Literature DB >> 16749418

Longitudinal long-term follow-up study of children with vertically acquired hepatitis C virus infection.

G V Zuccotti1, F Salvini, F Farina, C Agostoni, E Riva, M Giovannini.   

Abstract

Seventeen children with vertically acquired hepatitis C virus (HCV) infection were followed from birth for a mean of 104 months. Alanine aminotransferase (ALT) levels were increased significantly at 3 and 6 months of age but were stable thereafter. HCV polymerase chain reaction was positive at 3 months in 16 patients and at 12 months in one patient. Viral load remained stable during follow-up at a mean value of 5.4 +/- 0.4 log10. Mild chronic hepatitis was the most common histopathological feature on liver biopsy, occurring in six of the seven children biopsied at a mean age of 4.0 +/- 2.4 years. Genotype did not seem to be related to the type of liver involvement. The results of this study suggest that vertically acquired HCV infection has a benign course in children, despite the presence of viraemia and persistent alterations in ALT levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16749418     DOI: 10.1177/147323000603400212

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

1.  Surveying Infections among Pregnant Women in the Niger Delta, Nigeria.

Authors:  Fi Buseri; E Seiyaboh; Za Jeremiah
Journal:  J Glob Infect Dis       Date:  2010-09

2.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

3.  Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt.

Authors:  Lenka Benova; Susanne F Awad; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  Hepatology       Date:  2015-01-22       Impact factor: 17.425

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.